Recruiting

Biomarkers Development

Sponsor:

Nucleix Ltd.

Code:

NCT06245876

Conditions

Lung Cancer

Eligibility Criteria

Sex: All

Age: 20 - 70+

Healthy Volunteers: Accepted

Interventions

Blood collection

Study Details

Brief summary:

This study is part of the development of a non-invasive lung cancer screening test which aim to identify early-stage lung cancer in patients at high risk for lung cancer.

Conditions

Lung Cancer

Study ID

NCT06245876

Start date

May 17, 2022

Status verified date

Feb, 2024

Completion date

Dec 31, 2025

Anticipated

Primary completion date

Dec 31, 2025

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 20 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria - Cases:

  • Age 50-80 years
  • Subjects who are currently smoking or former smokers, with at least 20 pack-years
  • Subjects with either A high suspicion for lung cancer, with planned biopsy or surgery to establish a definitive diagnosis within 60 days after enrollment or treatment naive lung cancer patients confirmed by pathology.

Exclusion Criteria - Cases

  • Known diagnosis or treatment of cancer from any kind in the past 5 years, except of fully resected non-melanoma skin cancer or fully-resected carcinoma in situ of the cervix and except from the current lung cancer

Inclusion Criteria - USPSTF risk

  • Age 50-80 years
  • Subjects who are currently smoking or former smokers, with at least 20 pack-years

Exclusion Criteria - USPSTF risk

- Known diagnosis or treatment of cancer of any kind in the past 5 years, except for fully resected non-melanoma skin cancer or fully-resected carcinoma in situ of the cervix

Inclusion Criteria - Healthy controls

  • Age 20-80 years
  • Never smoker or current / previous smoker < 20 pack year history

Exclusion Criteria - Healthy Controls

  • Known diagnosis or treatment of cancer of any kind in the past (lifetime), except for fully resected non-melanoma skin cancer or fully-resected carcinoma in situ of the cervix.
  • Not previously diagnosed with a lung lesion highly suspicious for cancer
  • Under follow up or work up for any lesion suspicious for any type of cancer
  • Presenting with fever with body temperature 100.4°F (38°C) or higher
  • Acute exacerbation or flare of an inflammatory condition requiring escalation in medical therapy within 14 days prior to blood draw
  • Pregnancy
  • Any history of blood product transfusion within 30 days prior to blood draw

Study Design

Enrollment

6000 participants

Anticipated

Interventions and Outcome Measures

Arms

Cases Cohort

Subjects age 50-80 years old, with smoking history of at least 20 pack years with either (a) a high suspicion for lung cancer, who are planned to undergo biopsy or surgery to establish a definitive diagnosis after enrollment; or (b) confirmed primary lung cancer diagnosis, treatment naïve subjects.

USPSTF At Risk - Control Cohort

Healthy subjects aged 50-80 years old with smoking history of at least 20 pack years.

Healthy Control Cohort

Healthy subjects aged 20-80 years old which are non-smokers or with smoking history of less than 20 pack years.

Interventions

Blood collection

Blood collection

Primary outcome measure

  • Performance [ Time Frame: Day 1 ]

Central Contacts and Locations

Central contacts

Locations

Life Spring Clinical Research

Recruiting

Miami, Florida, United States, 33130

Emerald Coast OBGYN

Recruiting

Panama City, Florida, United States, 32405

Ochsner LSU Health Shreveport - Regional Urology

Recruiting

Shreveport, Louisiana, United States, 71106

Michigan Institute of Urology, P.C.

Recruiting

Troy, Michigan, United States, 48084

Urology San Antonio

Recruiting

San Antonio, Texas, United States, 78229

More Information

Sponsor

Nucleix Ltd.

Last update posted

Feb 12, 2024

Last verified

Feb, 2024

Keywords

  • Lung cancer screening

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Nucleix Ltd. on 2024-02-12.